clindamycin phosphate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
3909 24729-96-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clindamycin phosphate
  • cleocin phosphate
  • clindagel
  • clindamycin-2-phosphate
  • Molecular weight: 504.96
  • Formula: C18H34ClN2O8PS
  • CLOGP: -1.17
  • LIPINSKI: 1
  • HAC: 10
  • HDO: 5
  • TPSA: 148.79
  • ALOGS: -2.21
  • ROTB: 9
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Oct. 2, 1972 FDA PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 1803.83 10.53 1456 34947 309231 63143388
Acute generalised exanthematous pustulosis 265.75 10.53 129 36274 10970 63441649
Hidradenitis 154.36 10.53 59 36344 2787 63449832
Type IV hypersensitivity reaction 139.18 10.53 55 36348 2843 63449776
Clostridium difficile infection 134.63 10.53 122 36281 29800 63422819
Rash maculo-papular 131.78 10.53 124 36279 31772 63420847
Drug reaction with eosinophilia and systemic symptoms 110.97 10.53 116 36287 33720 63418899
Rash 109.16 10.53 619 35784 560252 62892367
Loss of employment 102.23 10.53 41 36362 2203 63450416
Dermatitis allergic 97.60 10.53 76 36327 15072 63437547
Toxic skin eruption 94.85 10.53 70 36333 12815 63439804
Pemphigus 82.29 10.53 6 36397 183720 63268899
Synovitis 81.21 10.53 7 36396 186911 63265708
Symmetrical drug-related intertriginous and flexural exanthema 77.97 10.53 23 36380 481 63452138
Glossodynia 74.28 10.53 8 36395 178868 63273751
Urticaria 71.20 10.53 233 36170 165569 63287050
Graft infection 70.75 10.53 17 36386 154 63452465
Hand deformity 69.19 10.53 6 36397 159451 63293168
Drug resistance 65.33 10.53 73 36330 22860 63429759
Multiple organ dysfunction syndrome 61.56 10.53 114 36289 56638 63395981
Arthropathy 59.74 10.53 30 36373 234762 63217857
Cellulitis 56.69 10.53 137 36266 81821 63370798
Premature delivery 56.60 10.53 78 36325 30203 63422416
Systemic lupus erythematosus 55.74 10.53 25 36378 208893 63243726
Clostridium difficile colitis 52.72 10.53 62 36341 20507 63432112
Pericarditis 51.87 10.53 7 36396 131572 63321047
Anti-cyclic citrullinated peptide antibody positive 51.44 10.53 4 36399 116208 63336411
Abscess 50.84 10.53 55 36348 16613 63436006
Hepatic steatosis 50.64 10.53 72 36331 28697 63423922
Anaphylactic reaction 49.52 10.53 114 36289 65986 63386633
Gastric disorder 48.19 10.53 81 36322 37288 63415331
Joint swelling 47.97 10.53 71 36332 327595 63125024
Alopecia 46.69 10.53 76 36327 337460 63115159
Pathogen resistance 45.39 10.53 34 36369 6364 63446255
Erythema 43.66 10.53 208 36195 175543 63277076
Rheumatoid arthritis 42.24 10.53 50 36353 253769 63198850
Helicobacter infection 41.61 10.53 3 36400 92782 63359837
Klebsiella infection 40.63 10.53 36 36367 8530 63444089
Discomfort 38.78 10.53 24 36379 167350 63285269
Osteonecrosis of jaw 38.64 10.53 71 36332 35052 63417567
Death 38.45 10.53 100 36303 374281 63078338
Infusion related reaction 38.10 10.53 51 36352 245470 63207149
Pneumococcal infection 38.08 10.53 13 36390 442 63452177
Skin lesion 37.51 10.53 65 36338 30656 63421963
Tubo-ovarian abscess 36.42 10.53 12 36391 365 63452254
Type I hypersensitivity 36.19 10.53 22 36381 2920 63449699
Toxic epidermal necrolysis 35.48 10.53 57 36346 25277 63427342
Hepatitis infectious mononucleosis 35.16 10.53 9 36394 108 63452511
Pseudomembranous colitis 35.05 10.53 22 36381 3090 63449529
Toxic shock syndrome streptococcal 34.43 10.53 9 36394 118 63452501
Peripheral swelling 33.91 10.53 63 36340 265879 63186740
Diarrhoea 33.65 10.53 586 35817 714780 62737839
Product use in unapproved indication 32.23 10.53 194 36209 178886 63273733
Septic shock 30.71 10.53 96 36307 66533 63386086
Idiosyncratic drug reaction 30.51 10.53 13 36390 815 63451804
Skin odour abnormal 30.05 10.53 16 36387 1650 63450969
Abscess neck 29.63 10.53 12 36391 661 63451958
Cholecystitis chronic 29.54 10.53 33 36370 10328 63442291
Wound 29.53 10.53 30 36373 163233 63289386
Upper respiratory tract infection bacterial 29.42 10.53 8 36395 123 63452496
Musculoskeletal stiffness 27.98 10.53 39 36364 184579 63268040
Contraindicated product administered 27.35 10.53 52 36351 217596 63235023
Acute kidney injury 27.16 10.53 250 36153 263165 63189454
Fatigue 26.83 10.53 354 36049 887674 62564945
Leukocytosis 26.74 10.53 51 36352 25884 63426735
Drug eruption 26.65 10.53 54 36349 28640 63423979
Fibromyalgia 25.94 10.53 7 36396 80413 63372206
Mastitis 25.68 10.53 17 36386 2615 63450004
Pneumothorax 24.73 10.53 38 36365 16223 63436396
Rash morbilliform 24.32 10.53 18 36385 3307 63449312
Pruritus 24.29 10.53 315 36088 361138 63091481
Tubulointerstitial nephritis 24.15 10.53 42 36361 19861 63432758
Reaction to azo-dyes 24.09 10.53 5 36398 21 63452598
Toxic shock syndrome 23.87 10.53 11 36392 831 63451788
Eosinophilia 23.77 10.53 45 36358 22711 63429908
Dermatitis acneiform 23.70 10.53 21 36382 4975 63447644
Blood testosterone increased 23.02 10.53 7 36396 163 63452456
Drug intolerance 22.97 10.53 95 36308 308566 63144053
Sepsis syndrome 22.69 10.53 11 36392 931 63451688
Type IIb hyperlipidaemia 22.61 10.53 5 36398 30 63452589
Blood cholesterol increased 22.45 10.53 13 36390 94019 63358600
Staphylococcal infection 22.39 10.53 63 36340 41193 63411426
Confusional state 22.11 10.53 66 36337 236314 63216305
Pyrexia 21.89 10.53 385 36018 470093 62982526
Completed suicide 21.84 10.53 31 36372 145642 63306977
Acne 21.83 10.53 44 36359 23249 63429370
Puerperal pyrexia 21.70 10.53 5 36398 37 63452582
Type 2 diabetes mellitus 21.68 10.53 5 36398 63863 63388756
Pustule 21.66 10.53 13 36390 1686 63450933
Oesophagitis 21.33 10.53 34 36369 14974 63437645
Oxygen saturation abnormal 21.21 10.53 17 36386 3512 63449107
Intentional overdose 21.17 10.53 8 36395 74144 63378475
Escherichia infection 21.10 10.53 31 36372 12723 63439896
Hypoglossal nerve paresis 20.93 10.53 6 36397 113 63452506
Weight increased 20.84 10.53 78 36325 260714 63191905
Respiratory gas exchange disorder 20.69 10.53 8 36395 390 63452229
Swelling of eyelid 20.68 10.53 16 36387 3140 63449479
Sleep disorder due to general medical condition, insomnia type 20.05 10.53 3 36400 52214 63400405
Prothrombin time prolonged 19.95 10.53 26 36377 9538 63443081
Stevens-Johnson syndrome 19.75 10.53 44 36359 24906 63427713
Surgical failure 19.49 10.53 10 36393 956 63451663
Folliculitis 19.39 10.53 8 36395 70309 63382310
Lower respiratory tract infection bacterial 19.30 10.53 8 36395 468 63452151
Scar 19.28 10.53 31 36372 13751 63438868
Wound secretion 19.16 10.53 18 36385 4596 63448023
Cyst 18.76 10.53 31 36372 14068 63438551
Breast abscess 18.62 10.53 12 36391 1764 63450855
Mycobacterial infection 18.58 10.53 12 36391 1771 63450848
Preterm premature rupture of membranes 18.53 10.53 11 36392 1398 63451221
Rash erythematous 18.44 10.53 60 36343 42450 63410169
Pneumomediastinum 18.34 10.53 11 36392 1425 63451194
Exposure during pregnancy 18.28 10.53 152 36251 155395 63297224
Lymphadenopathy 18.26 10.53 56 36347 38402 63414217
Subcutaneous abscess 18.01 10.53 19 36384 5577 63447042
Bronchial obstruction 17.85 10.53 11 36392 1496 63451123
Acute hepatic failure 17.63 10.53 35 36368 18292 63434327
Drug ineffective for unapproved indication 17.50 10.53 51 36352 34012 63418607
Osteomyelitis 17.45 10.53 43 36360 25977 63426642
Acinetobacter infection 17.35 10.53 11 36392 1572 63451047
Toxicity to various agents 17.22 10.53 78 36325 247172 63205447
Nephritis allergic 17.22 10.53 6 36397 217 63452402
Antibiotic level below therapeutic 17.20 10.53 4 36399 31 63452588
Dysbiosis 17.19 10.53 9 36394 897 63451722
Thyroxine increased 17.16 10.53 8 36395 621 63451998
Swelling face 17.12 10.53 77 36326 63398 63389221
Pneumonia necrotising 16.26 10.53 7 36396 450 63452169
Irritable bowel syndrome 16.24 10.53 14 36389 82398 63370221
Skin exfoliation 16.21 10.53 58 36345 43044 63409575
Syndactyly 16.11 10.53 7 36396 460 63452159
Candida infection 16.08 10.53 44 36359 28307 63424312
Emotional distress 16.02 10.53 48 36355 32501 63420118
Allergy to metals 15.97 10.53 8 36395 727 63451892
Drug-induced liver injury 15.88 10.53 55 36348 40167 63412452
Hepatic enzyme increased 15.84 10.53 61 36342 202267 63250352
Stomatitis 15.84 10.53 35 36368 138690 63313929
Oesophageal ulcer 15.81 10.53 16 36387 4474 63448145
Venous haemorrhage 15.54 10.53 6 36397 291 63452328
Cardiac failure congestive 15.27 10.53 98 36305 92335 63360284
Perihepatic discomfort 15.24 10.53 3 36400 9 63452610
Anterior segment ischaemia 15.13 10.53 4 36399 55 63452564
Documented hypersensitivity to administered product 15.08 10.53 7 36396 538 63452081
Necrotising fasciitis 14.86 10.53 13 36390 3028 63449591
Necrosis 14.83 10.53 17 36386 5470 63447149
Vulval abscess 14.62 10.53 8 36395 871 63451748
Factor V inhibition 14.62 10.53 5 36398 171 63452448
Post infection glomerulonephritis 14.57 10.53 3 36400 12 63452607
Papule 14.33 10.53 17 36386 5674 63446945
Clostridial infection 14.29 10.53 15 36388 4377 63448242
Injection site erythema 14.23 10.53 16 36387 83158 63369461
Cleft lip and palate 14.06 10.53 7 36396 628 63451991
Joint vibration 14.03 10.53 3 36400 15 63452604
Erosive oesophagitis 14.00 10.53 10 36393 1740 63450879
Acne pustular 13.99 10.53 5 36398 195 63452424
Superinfection bacterial 13.98 10.53 7 36396 636 63451983
Infection protozoal 13.87 10.53 3 36400 16 63452603
Serratia infection 13.86 10.53 8 36395 965 63451654
Lower respiratory tract infection 13.81 10.53 35 36368 132272 63320347
Asthenia 13.79 10.53 147 36256 383457 63069162
Pulmonary fibrosis 13.74 10.53 3 36400 39806 63412813
Chronic kidney disease 13.72 10.53 57 36346 45341 63407278
Weaning failure 13.66 10.53 6 36397 405 63452214
Infected skin ulcer 13.52 10.53 11 36392 2321 63450298
Vulvovaginal discomfort 13.33 10.53 11 36392 2367 63450252
Babesiosis 13.33 10.53 5 36398 224 63452395
Sedation 13.25 10.53 3 36400 38806 63413813
Swelling 13.20 10.53 98 36305 275280 63177339
Megacolon 13.19 10.53 10 36393 1905 63450714
Face oedema 13.13 10.53 33 36370 20179 63432440
Sexual inhibition 13.05 10.53 3 36400 22 63452597
Necrotising oesophagitis 12.97 10.53 6 36397 457 63452162
Multi-organ disorder 12.93 10.53 9 36394 1503 63451116
Geotrichum infection 12.84 10.53 6 36397 468 63452151
Pseudomonas infection 12.75 10.53 23 36380 11190 63441429
Deep vein thrombosis 12.72 10.53 87 36316 83713 63368906
Tinea infection 12.70 10.53 8 36395 1130 63451489
Lemierre syndrome 12.66 10.53 4 36399 106 63452513
Acute respiratory failure 12.62 10.53 46 36357 34439 63418180
Coma 12.60 10.53 11 36392 64353 63388266
Fungal infection 12.51 10.53 48 36355 36826 63415793
Serum sickness-like reaction 12.42 10.53 6 36397 504 63452115
Hip arthroplasty 12.23 10.53 6 36397 47640 63404979
Hyphaema 12.04 10.53 5 36398 294 63452325
Anhedonia 11.83 10.53 22 36381 10952 63441667
Plasma cell myeloma 11.81 10.53 3 36400 35902 63416717
Abortion spontaneous 11.80 10.53 56 36347 47139 63405480
Neonatal respiratory distress syndrome 11.72 10.53 11 36392 2807 63449812
Injury 11.69 10.53 77 36326 73170 63379449
Ill-defined disorder 11.66 10.53 18 36385 81737 63370882
Abdominal sepsis 11.63 10.53 8 36395 1311 63451308
Tooth extraction 11.60 10.53 21 36382 10243 63442376
Skin infection 11.37 10.53 26 36377 14976 63437643
Skin discharge 11.36 10.53 3 36400 41 63452578
Adenocarcinoma 11.29 10.53 11 36392 2939 63449680
Abscess jaw 11.19 10.53 8 36395 1394 63451225
Bartholinitis 11.16 10.53 3 36400 44 63452575
White matter lesion 11.12 10.53 9 36394 1886 63450733
Drug ineffective 11.11 10.53 717 35686 1044048 62408571
Tracheal haemorrhage 11.05 10.53 4 36399 162 63452457
Shock 10.98 10.53 34 36369 23429 63429190
Hormone level abnormal 10.92 10.53 10 36393 2473 63450146
Hypoglycaemia 10.89 10.53 11 36392 60054 63392565
Bone sequestrum 10.83 10.53 8 36395 1466 63451153
Wound complication 10.79 10.53 12 36391 3735 63448884
Sphingomonas paucimobilis infection 10.75 10.53 3 36400 51 63452568
Hyperleukocytosis 10.74 10.53 6 36397 680 63451939
Hepatorenal failure 10.68 10.53 6 36397 688 63451931
Haemodynamic instability 10.64 10.53 19 36384 9171 63443448
Product physical consistency issue 10.64 10.53 6 36397 693 63451926
Exophthalmos 10.63 10.53 8 36395 1508 63451111
Bezoar 10.58 10.53 8 36395 1518 63451101
Clostridium test positive 10.53 10.53 11 36392 3190 63449429

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 281 11.77 287 20090 80242 34856312
Type IV hypersensitivity reaction 218.92 11.77 65 20312 1369 34935185
Rash maculo-papular 208.47 11.77 155 20222 28296 34908258
Acute generalised exanthematous pustulosis 155.78 11.77 77 20300 6699 34929855
Drug reaction with eosinophilia and systemic symptoms 120.97 11.77 121 20256 32891 34903663
Rash 119.20 11.77 341 20036 222411 34714143
Drug ineffective 102.16 11.77 529 19848 456222 34480332
Clostridium difficile colitis 81.55 11.77 70 20307 15660 34920894
Kounis syndrome 53.11 11.77 27 20350 2491 34934063
Death 52.66 11.77 95 20282 397954 34538600
Methaemoglobinaemia 49.42 11.77 29 20348 3552 34933002
Drug resistance 47.95 11.77 67 20310 25860 34910694
Graft infection 45.57 11.77 15 20362 447 34936107
Toxic skin eruption 44.02 11.77 43 20334 11342 34925212
Drug-induced liver injury 42.52 11.77 67 20310 28765 34907789
Oesophageal ulcer 40.49 11.77 25 20352 3356 34933198
Pseudomembranous colitis 39.56 11.77 23 20354 2768 34933786
Dermatitis allergic 38.69 11.77 32 20345 6798 34929756
Pruritus 37.52 11.77 173 20204 141808 34794746
Abscess 37.28 11.77 40 20337 11777 34924777
Drug abuse 36.06 11.77 7 20370 99089 34837465
Pathogen resistance 35.15 11.77 35 20342 9447 34927107
Hidradenitis 33.17 11.77 15 20362 1067 34935487
Cellulitis 33.06 11.77 86 20291 52865 34883689
Surgical failure 32.82 11.77 8 20369 76 34936478
Erythema 32.79 11.77 120 20257 88660 34847894
Drug eruption 31.81 11.77 48 20329 19850 34916704
Abscess of salivary gland 31.78 11.77 6 20371 13 34936541
Necrotising fasciitis 31.14 11.77 22 20355 3700 34932854
Rash erythematous 30.07 11.77 53 20324 24924 34911630
Electrocardiogram U wave present 29.90 11.77 6 20371 20 34936534
Venolymphatic malformation 29.25 11.77 6 20371 23 34936531
Drug ineffective for unapproved indication 28.14 11.77 50 20327 23665 34912889
Glomerulosclerosis 26.98 11.77 12 20365 821 34935733
Perineal infection 26.62 11.77 11 20366 628 34935926
Scrotal infection 26.39 11.77 11 20366 642 34935912
Infected dermal cyst 26.16 11.77 12 20365 882 34935672
Mucormycosis 25.93 11.77 24 20353 5918 34930636
Optic nerve operation 25.84 11.77 10 20367 480 34936074
Tubulointerstitial nephritis 25.81 11.77 45 20332 20979 34915575
Resorption bone increased 25.05 11.77 8 20369 216 34936338
Overgrowth bacterial 24.92 11.77 7 20370 120 34936434
Cholestatic liver injury 24.61 11.77 16 20361 2348 34934206
Skin graft failure 23.86 11.77 7 20370 141 34936413
Arteriovenous fistula 23.68 11.77 12 20365 1099 34935455
Megacolon 23.26 11.77 14 20363 1796 34934758
Stevens-Johnson syndrome 23.02 11.77 40 20337 18599 34917955
Rash morbilliform 22.98 11.77 17 20360 3070 34933484
Dermal cyst 22.85 11.77 14 20363 1853 34934701
Tooth injury 22.76 11.77 12 20365 1193 34935361
Osteomyelitis salmonella 22.67 11.77 5 20372 29 34936525
Urinary tract inflammation 22.66 11.77 7 20370 169 34936385
Toxic epidermal necrolysis 22.36 11.77 43 20334 21603 34914951
Rash pustular 21.98 11.77 21 20356 5387 34931167
Renal hypoplasia 21.86 11.77 6 20371 94 34936460
Vanishing bile duct syndrome 21.71 11.77 11 20366 1007 34935547
Pyrexia 21.58 11.77 292 20085 332721 34603833
Anamnestic reaction 21.50 11.77 5 20372 38 34936516
Staphylococcal infection 21.26 11.77 54 20323 32706 34903848
Calcium deficiency 21.10 11.77 7 20370 214 34936340
Cutaneous vasculitis 20.13 11.77 18 20359 4245 34932309
Neuropsychiatric symptoms 19.98 11.77 10 20367 892 34935662
Pulmonary venous thrombosis 19.83 11.77 6 20371 135 34936419
Oesophagitis 19.80 11.77 31 20346 13230 34923324
Oesophagitis chemical 19.45 11.77 5 20372 60 34936494
General physical health deterioration 19.32 11.77 28 20349 128241 34808313
Gastrointestinal mucosa hyperaemia 19.12 11.77 7 20370 288 34936266
Osteomyelitis 19.11 11.77 34 20343 16102 34920452
Antibiotic level below therapeutic 18.81 11.77 5 20372 69 34936485
Conductive deafness 18.78 11.77 7 20370 303 34936251
Hepatitis cholestatic 18.50 11.77 23 20354 7924 34928630
Premature baby 17.88 11.77 37 20340 19596 34916958
Exophthalmos 17.61 11.77 8 20369 575 34935979
Clostridium test positive 17.57 11.77 15 20362 3327 34933227
Sialoadenitis 17.55 11.77 8 20369 580 34935974
Acne fulminans 17.48 11.77 6 20371 204 34936350
Vitamin A deficiency 17.25 11.77 4 20373 30 34936524
Rash pruritic 17.06 11.77 44 20333 26897 34909657
Swelling face 17.03 11.77 40 20337 23065 34913489
Leukocytosis 17.02 11.77 41 20336 24024 34912530
Tendon pain 16.90 11.77 14 20363 2981 34933573
Urine alcohol test positive 16.81 11.77 4 20373 34 34936520
Anal fistula 16.54 11.77 18 20359 5381 34931173
Intracranial aneurysm 16.37 11.77 11 20366 1707 34934847
Drug clearance increased 16.34 11.77 5 20372 117 34936437
Pouchitis 16.31 11.77 8 20369 683 34935871
Kidney fibrosis 15.98 11.77 12 20365 2216 34934338
Cardiac failure congestive 15.95 11.77 15 20362 83255 34853299
Biopsy liver 15.73 11.77 6 20371 277 34936277
Diarrhoea 15.61 11.77 316 20061 389596 34546958
Pneumatosis intestinalis 15.50 11.77 15 20362 3908 34932646
Folliculitis 15.37 11.77 16 20361 4550 34932004
Beta haemolytic streptococcal infection 15.18 11.77 7 20370 521 34936033
Umbilical hernia 15.05 11.77 16 20361 4661 34931893
Vitamin B1 deficiency 14.68 11.77 6 20371 333 34936221
Overdose 14.59 11.77 19 20358 91040 34845514
Erysipelas 14.53 11.77 16 20361 4847 34931707
Folate deficiency 14.46 11.77 9 20368 1225 34935329
Anal ulcer 14.44 11.77 8 20369 878 34935676
Debridement 14.30 11.77 8 20369 895 34935659
Mononucleosis syndrome 14.27 11.77 4 20373 68 34936486
Myocardial infarction 14.11 11.77 31 20346 121054 34815500
Arthrofibrosis 14.11 11.77 4 20373 71 34936483
Leg amputation 13.91 11.77 11 20366 2193 34934361
Memory impairment 13.89 11.77 4 20373 43314 34893240
Magnesium deficiency 13.66 11.77 4 20373 80 34936474
Cardiac failure 13.65 11.77 20 20357 91228 34845326
Laryngitis 13.56 11.77 11 20366 2274 34934280
Malaise 13.54 11.77 59 20318 185766 34750788
Device toxicity 13.38 11.77 3 20374 19 34936535
Post procedural fistula 13.35 11.77 4 20373 87 34936467
Staphylococcal sepsis 13.31 11.77 22 20355 9822 34926732
Coma 13.28 11.77 5 20372 45673 34890881
Dry gangrene 13.19 11.77 6 20371 433 34936121
Toxic shock syndrome streptococcal 13.12 11.77 3 20374 21 34936533
Cholestasis 13.11 11.77 40 20337 26908 34909646
Septic shock 13.06 11.77 79 20298 71755 34864799
Urticaria 12.90 11.77 71 20306 62306 34874248
Proctitis 12.89 11.77 11 20366 2438 34934116
Purpura 12.56 11.77 22 20355 10289 34926265
Multiple organ dysfunction syndrome 12.55 11.77 82 20295 76484 34860070
Low birth weight baby 12.53 11.77 19 20358 7886 34928668
Polycystic liver disease 12.53 11.77 4 20373 108 34936446
Anal haemorrhage 12.40 11.77 11 20366 2567 34933987
Completed suicide 12.40 11.77 24 20353 98144 34838410
Limb fracture 12.36 11.77 3 20374 28 34936526
Candida infection 12.33 11.77 30 20347 17685 34918869
Cerebrovascular accident 12.29 11.77 19 20358 84792 34851762
Gastrointestinal submucosal tumour 12.13 11.77 4 20373 120 34936434
Toxicity to various agents 12.07 11.77 68 20309 200294 34736260
SAPHO syndrome 11.99 11.77 5 20372 292 34936262
Blood pressure systolic abnormal 11.81 11.77 13 20364 3935 34932619
Acute kidney injury 11.79 11.77 246 20131 304742 34631812
Hepatocellular injury 11.78 11.77 34 20343 22177 34914377

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 493.27 10.15 724 45053 298192 79400419
Acute generalised exanthematous pustulosis 369.74 10.15 186 45591 17068 79681543
Type IV hypersensitivity reaction 354.84 10.15 120 45657 3961 79694650
Rash maculo-papular 339.16 10.15 271 45506 55807 79642804
Drug reaction with eosinophilia and systemic symptoms 230.12 10.15 231 45546 64013 79634598
Rash 207.64 10.15 765 45012 577593 79121018
Toxic skin eruption 135.25 10.15 108 45669 22185 79676426
Hidradenitis 126.22 10.15 52 45725 2992 79695619
Clostridium difficile colitis 119.08 10.15 118 45659 32165 79666446
Drug ineffective 112.82 10.15 1027 44750 1079886 78618725
Graft infection 108.00 10.15 32 45745 679 79697932
Drug resistance 104.42 10.15 125 45652 42088 79656523
Loss of employment 96.55 10.15 41 45736 2546 79696065
Abscess 84.84 10.15 84 45693 22867 79675744
Clostridium difficile infection 82.79 10.15 112 45665 42573 79656038
Cellulitis 72.86 10.15 180 45597 108880 79589731
Pathogen resistance 69.43 10.15 61 45716 14281 79684330
Symmetrical drug-related intertriginous and flexural exanthema 69.01 10.15 24 45753 862 79697749
Death 67.59 10.15 140 45637 566374 79132237
Drug abuse 65.81 10.15 8 45769 162683 79535928
Synovitis 64.59 10.15 6 45771 150728 79547883
Drug-induced liver injury 62.03 10.15 125 45652 65992 79632619
Erythema 61.81 10.15 273 45504 223017 79475594
Pseudomembranous colitis 60.52 10.15 38 45739 5336 79693275
Urticaria 56.31 10.15 233 45544 184968 79513643
Oesophageal ulcer 56.08 10.15 40 45737 6935 79691676
Drug eruption 53.63 10.15 93 45684 43842 79654769
Tubulointerstitial nephritis 53.44 10.15 86 45691 38149 79660462
Pyrexia 53.16 10.15 609 45168 678100 79020511
Joint swelling 52.42 10.15 53 45724 288593 79410018
Methaemoglobinaemia 49.66 10.15 34 45743 5523 79693088
Leukocytosis 49.19 10.15 89 45688 43366 79655245
Surgical failure 47.05 10.15 18 45759 851 79697760
Rash erythematous 46.95 10.15 103 45674 57666 79640945
Pruritus 46.52 10.15 386 45391 394262 79304349
Premature delivery 46.15 10.15 62 45715 23405 79675206
Staphylococcal infection 45.20 10.15 102 45675 58193 79640418
Toxic epidermal necrolysis 45.09 10.15 87 45690 44494 79654117
Multiple organ dysfunction syndrome 44.47 10.15 161 45616 120085 79578526
Rash morbilliform 44.30 10.15 33 45744 6117 79692494
Stevens-Johnson syndrome 42.80 10.15 79 45698 39087 79659524
Pericarditis 42.46 10.15 5 45772 104231 79594380
Hand deformity 42.29 10.15 5 45772 103914 79594697
Drug ineffective for unapproved indication 41.23 10.15 91 45686 51147 79647464
Kounis syndrome 40.17 10.15 27 45750 4255 79694356
Pemphigus 40.01 10.15 5 45772 99577 79599034
Type I hypersensitivity 39.51 10.15 27 45750 4371 79694240
Oesophagitis 38.64 10.15 58 45719 24231 79674380
Antibiotic level below therapeutic 37.80 10.15 9 45768 78 79698533
Arthropathy 37.62 10.15 28 45749 177083 79521528
Hepatitis infectious mononucleosis 37.12 10.15 10 45767 148 79698463
Anti-cyclic citrullinated peptide antibody positive 36.45 10.15 3 45774 83140 79615471
Septic shock 36.13 10.15 153 45624 122648 79575963
Completed suicide 35.31 10.15 54 45723 245713 79452898
Anaphylactic reaction 35.19 10.15 117 45660 83626 79614985
Necrotising fasciitis 33.92 10.15 28 45749 6022 79692589
Glossodynia 33.38 10.15 9 45768 103328 79595283
Klebsiella infection 33.17 10.15 43 45734 15677 79682934
Idiosyncratic drug reaction 33.14 10.15 16 45761 1341 79697270
Megacolon 32.70 10.15 22 45755 3473 79695138
Diarrhoea 32.51 10.15 696 45081 879793 78818818
Gastric disorder 31.85 10.15 68 45709 37365 79661246
Rheumatoid arthritis 31.71 10.15 44 45733 208426 79490185
Mucormycosis 31.30 10.15 31 45746 8438 79690173
Swelling face 30.37 10.15 100 45677 71112 79627499
Toxic shock syndrome streptococcal 29.53 10.15 8 45769 121 79698490
Tubo-ovarian abscess 29.47 10.15 10 45767 333 79698278
Helicobacter infection 29.26 10.15 3 45774 69701 79628910
Abscess neck 28.89 10.15 14 45763 1183 79697428
Rash pustular 28.79 10.15 34 45743 11277 79687334
Abscess of salivary gland 28.75 10.15 6 45771 26 79698585
Pneumococcal infection 28.67 10.15 13 45764 945 79697666
Mastitis 28.53 10.15 17 45760 2174 79696437
Clostridium test positive 28.37 10.15 26 45751 6428 79692183
Toxicity to various agents 28.32 10.15 135 45642 421405 79277206
Toxic shock syndrome 28.32 10.15 14 45763 1235 79697376
Acute hepatic failure 28.31 10.15 57 45720 30056 79668555
Cholestatic liver injury 27.98 10.15 23 45754 4918 79693693
Candida infection 27.56 10.15 65 45712 38149 79660462
Perineal infection 27.52 10.15 12 45765 795 79697816
Cholecystitis chronic 27.27 10.15 31 45746 9875 79688736
Scrotal infection 27.22 10.15 11 45766 602 79698009
Hepatic steatosis 27.01 10.15 64 45713 37674 79660937
Eosinophilia 26.30 10.15 71 45706 45274 79653337
Intentional overdose 26.29 10.15 14 45763 105946 79592665
Optic nerve operation 25.99 10.15 10 45767 480 79698131
Systemic lupus erythematosus 25.92 10.15 19 45758 121130 79577481
Escherichia infection 25.82 10.15 41 45736 17976 79680635
Skin lesion 25.77 10.15 67 45710 41777 79656834
Coma 25.41 10.15 13 45764 100636 79597975
Reaction to azo-dyes 25.39 10.15 5 45772 15 79698596
Hypoglossal nerve paresis 25.14 10.15 7 45770 118 79698493
Glomerulosclerosis 23.74 10.15 12 45765 1110 79697501
Alopecia 23.63 10.15 62 45715 231293 79467318
Acute kidney injury 23.63 10.15 424 45353 518980 79179631
Erysipelas 23.40 10.15 30 45747 10820 79687791
Purpura 23.39 10.15 41 45736 19486 79679125
Lymphadenopathy 22.91 10.15 75 45702 53172 79645439
Fungal infection 22.85 10.15 64 45713 41684 79656927
Peripheral swelling 22.71 10.15 79 45698 269538 79429073
Pseudomonas infection 22.63 10.15 42 45735 20861 79677750
Type IIb hyperlipidaemia 22.61 10.15 5 45772 30 79698581
Infected dermal cyst 22.45 10.15 12 45765 1246 79697365
Anamnestic reaction 22.33 10.15 5 45772 32 79698579
Sialoadenitis 22.16 10.15 14 45763 1987 79696624
Puerperal pyrexia 22.07 10.15 5 45772 34 79698577
Overgrowth bacterial 21.69 10.15 7 45770 199 79698412
Arteriovenous fistula 21.62 10.15 12 45765 1342 79697269
Post infection glomerulonephritis 21.61 10.15 6 45771 100 79698511
Confusional state 21.25 10.15 102 45675 317895 79380716
Acne fulminans 21.20 10.15 7 45770 214 79698397
Osteomyelitis salmonella 21.03 10.15 5 45772 43 79698568
Product use in unapproved indication 21.02 10.15 228 45549 250131 79448480
Skin graft failure 20.87 10.15 7 45770 225 79698386
Overdose 20.67 10.15 47 45730 184159 79514452
Suicide attempt 20.51 10.15 11 45766 82921 79615690
Conductive deafness 20.49 10.15 7 45770 238 79698373
Electrocardiogram U wave present 20.17 10.15 6 45771 129 79698482
Fatigue 20.04 10.15 395 45382 929332 78769279
Osteomyelitis 19.60 10.15 52 45725 32813 79665798
Ophthalmoplegia 19.59 10.15 15 45762 2897 79695714
Clostridial infection 19.44 10.15 20 45757 5694 79692917
Pulmonary venous thrombosis 19.24 10.15 6 45771 152 79698459
Acute respiratory distress syndrome 18.89 10.15 62 45715 44005 79654606
Osteonecrosis of jaw 18.70 10.15 61 45716 43165 79655446
Discomfort 18.61 10.15 27 45750 125590 79573021
Musculoskeletal stiffness 18.56 10.15 46 45731 174962 79523649
Muscle injury 18.20 10.15 3 45774 48558 79650053
Wound secretion 18.12 10.15 20 45757 6168 79692443
Breast abscess 18.12 10.15 11 45766 1455 79697156
Blood cholesterol increased 18.08 10.15 13 45764 83707 79614904
Drug intolerance 18.06 10.15 84 45693 264035 79434576
Eye swelling 17.99 10.15 44 45733 26424 79672187
Urine alcohol test positive 17.94 10.15 4 45773 25 79698586
Sepsis syndrome 17.77 10.15 11 45766 1506 79697105
Skin infection 17.71 10.15 35 45742 18210 79680401
Oxygen saturation abnormal 17.36 10.15 17 45760 4565 79694046
Face oedema 17.27 10.15 45 45732 28091 79670520
Pustule 17.18 10.15 12 45765 2013 79696598
Tooth injury 17.16 10.15 12 45765 2016 79696595
Scar 17.04 10.15 31 45746 15165 79683446
SAPHO syndrome 16.81 10.15 7 45770 414 79698197
Skin odour abnormal 16.57 10.15 12 45765 2129 79696482
Cutaneous vasculitis 16.52 10.15 22 45755 8230 79690381
Somnolence 16.34 10.15 76 45701 238905 79459706
Urinary tract inflammation 16.31 10.15 6 45771 254 79698357
Asthenia 16.20 10.15 202 45575 511487 79187124
Vanishing bile duct syndrome 16.17 10.15 11 45766 1767 79696844
Weaning failure 16.17 10.15 8 45769 707 79697904
Swelling of eyelid 16.07 10.15 15 45762 3796 79694815
Dermal cyst 16.06 10.15 13 45764 2719 79695892
Neuropsychiatric symptoms 15.92 10.15 10 45767 1405 79697206
Prothrombin time prolonged 15.90 10.15 32 45745 16867 79681744
Sedation 15.87 10.15 5 45772 51890 79646721
Gastrointestinal mucosa hyperaemia 15.85 10.15 7 45770 478 79698133
Thyroxine increased 15.75 10.15 8 45769 748 79697863
Skin exfoliation 15.69 10.15 68 45709 55032 79643579
Sleep disorder due to general medical condition, insomnia type 15.65 10.15 3 45774 43553 79655058
Infected skin ulcer 15.53 10.15 14 45763 3387 79695224
Rash macular 15.52 10.15 44 45733 28855 79669756
Erosive oesophagitis 15.46 10.15 13 45764 2869 79695742
Vulval abscess 15.42 10.15 8 45769 782 79697829
Postoperative wound infection 15.25 10.15 27 45750 12934 79685677
Perihepatic discomfort 15.24 10.15 3 45774 9 79698602
Post procedural fistula 15.21 10.15 6 45771 308 79698303
Odynophagia 15.17 10.15 25 45752 11302 79687309
Anterior segment ischaemia 15.12 10.15 4 45773 55 79698556
Allergy to metals 15.07 10.15 7 45770 538 79698073
Respiratory gas exchange disorder 14.86 10.15 8 45769 843 79697768
Tinea infection 14.79 10.15 9 45768 1196 79697415
Dysbiosis 14.69 10.15 9 45768 1210 79697401
Dermatitis acneiform 14.68 10.15 23 45754 9970 79688641
Leg amputation 14.64 10.15 14 45763 3652 79694959
Venous haemorrhage 14.52 10.15 6 45771 348 79698263
Abscess limb 14.48 10.15 19 45758 7008 79691603
Tendon pain 14.39 10.15 17 45760 5641 79692970
Rash pruritic 14.38 10.15 80 45697 71549 79627062
Babesiosis 14.37 10.15 6 45771 357 79698254
Aspergillus infection 14.26 10.15 33 45744 19128 79679483
Hepatic cytolysis 14.25 10.15 41 45736 27110 79671501
Weight increased 14.20 10.15 97 45680 277289 79421322
Subcutaneous abscess 14.12 10.15 20 45757 7929 79690682
Neoplasm progression 14.08 10.15 6 45771 51676 79646935
Interstitial lung disease 14.08 10.15 27 45750 112573 79586038
Joint vibration 14.02 10.15 3 45774 15 79698596
Acute febrile neutrophilic dermatosis 13.99 10.15 14 45763 3858 79694753
Lower respiratory tract infection bacterial 13.99 10.15 8 45769 948 79697663
Pulmonary fibrosis 13.95 10.15 4 45773 44108 79654503
Bronchial obstruction 13.85 10.15 12 45765 2756 79695855
Acinetobacter infection 13.82 10.15 12 45765 2765 79695846
Oesophagitis chemical 13.72 10.15 4 45773 80 79698531
Clostridium colitis 13.59 10.15 12 45765 2827 79695784
Fungal sepsis 13.59 10.15 10 45767 1820 79696791
Infection protozoal 13.56 10.15 3 45774 18 79698593
Tremor 13.54 10.15 51 45726 170032 79528579
Injection site erythema 13.46 10.15 15 45762 78182 79620429
Device toxicity 13.42 10.15 3 45774 19 79698592
Cerebral toxoplasmosis 13.39 10.15 11 45766 2351 79696260
Vitamin A deficiency 13.28 10.15 4 45773 90 79698521
Dermatitis allergic 13.25 10.15 31 45746 18099 79680512
Muscle necrosis 13.22 10.15 9 45768 1449 79697162
Hypersensitivity vasculitis 13.13 10.15 18 45759 6925 79691686
Resorption bone increased 13.12 10.15 9 45768 1466 79697145
Scedosporium infection 13.10 10.15 9 45768 1469 79697142
Orthostatic hypotension 13.10 10.15 8 45769 56156 79642455
Normochromic anaemia 13.02 10.15 6 45771 453 79698158
Skin disorder 13.01 10.15 46 45731 33897 79664714
Mycobacterial infection 12.77 10.15 13 45764 3655 79694956
Hepatitis cholestatic 12.76 10.15 26 45751 13826 79684785
Angioedema 12.75 10.15 81 45696 75954 79622657
Haemorrhagic vasculitis 12.73 10.15 4 45773 104 79698507
Infusion related reaction 12.54 10.15 79 45698 230158 79468453
Drug clearance increased 12.52 10.15 5 45772 265 79698346
Arthrofibrosis 12.38 10.15 4 45773 114 79698497
Skin reaction 12.32 10.15 28 45749 16040 79682571
Infective uveitis 12.21 10.15 3 45774 30 79698581
Respiratory failure 12.19 10.15 158 45619 180753 79517858
Type 2 diabetes mellitus 12.16 10.15 9 45768 57113 79641498
Platelet count decreased 12.10 10.15 64 45713 194600 79504011
Gastrointestinal submucosal tumour 11.97 10.15 4 45773 127 79698484
Acute myocardial infarction 11.97 10.15 16 45761 77020 79621591
Bartholinitis 11.95 10.15 3 45774 33 79698578
Candida osteomyelitis 11.87 10.15 3 45774 34 79698577
Mononucleosis syndrome 11.85 10.15 4 45773 131 79698480
Exophthalmos 11.83 10.15 9 45768 1721 79696890
Tooth extraction 11.79 10.15 22 45755 10973 79687638
Skin oedema 11.78 10.15 9 45768 1732 79696879
Accidental overdose 11.78 10.15 4 45773 39577 79659034
Calcium deficiency 11.77 10.15 7 45770 892 79697719
Intracranial mass 11.73 10.15 10 45767 2249 79696362
Amenorrhoea 11.71 10.15 18 45759 7674 79690937
Serratia infection 11.62 10.15 9 45768 1767 79696844
Upper respiratory tract infection bacterial 11.57 10.15 4 45773 141 79698470
Limb fracture 11.57 10.15 3 45774 38 79698573
Cerebrovascular accident 11.45 10.15 48 45729 155244 79543367
Documented hypersensitivity to administered product 11.43 10.15 7 45770 940 79697671
Pneumothorax 11.39 10.15 39 45738 28284 79670327
Kidney fibrosis 11.36 10.15 12 45765 3523 79695088
Vulvovaginal discomfort 11.35 10.15 9 45768 1829 79696782
Anal ulcer 11.30 10.15 8 45769 1370 79697241
Sensory disturbance 11.26 10.15 26 45751 15051 79683560
Biopsy liver 11.23 10.15 6 45771 622 79697989
Myocardial infarction 11.19 10.15 61 45716 184068 79514543
Serum sickness-like reaction 11.17 10.15 6 45771 629 79697982
Pouchitis 11.15 10.15 7 45770 982 79697629
Lemierre syndrome 11.14 10.15 4 45773 158 79698453
Pneumomediastinum 10.99 10.15 12 45765 3655 79694956
Adverse event 10.98 10.15 11 45766 60203 79638408
Intentional product misuse 10.90 10.15 24 45753 95141 79603470
Decreased appetite 10.88 10.15 135 45642 342283 79356328
Polycystic liver disease 10.88 10.15 4 45773 169 79698442
Factor V inhibition 10.87 10.15 5 45772 376 79698235
Umbilical hernia 10.82 10.15 15 45762 5830 79692781
Blood testosterone increased 10.76 10.15 7 45770 1045 79697566
Head injury 10.74 10.15 4 45773 37365 79661246
Eyelid oedema 10.66 10.15 24 45753 13663 79684948
Vitamin B1 deficiency 10.64 10.15 6 45771 692 79697919
Pharyngeal abscess 10.62 10.15 6 45771 694 79697917
White matter lesion 10.60 10.15 9 45768 2013 79696598
Lip swelling 10.53 10.15 49 45728 40862 79657749
Insomnia 10.53 10.15 90 45687 245080 79453531
Wound 10.49 10.15 33 45744 116146 79582465
Cyst 10.48 10.15 24 45753 13816 79684795
Haemolytic anaemia 10.43 10.15 28 45749 17792 79680819
Nephritis allergic 10.39 10.15 6 45771 724 79697887
Sleep disorder 10.32 10.15 21 45756 85656 79612955
Anal fistula 10.22 10.15 16 45761 6928 79691683

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA CS M0515779 Lincosamides
FDA PE N0000009982 Decreased Sebaceous Gland Activity
FDA EPC N0000175443 Lincosamide Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:78298 environmental contaminants
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors
FDA PE N0000175731 Neuromuscular Blockade

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Anaerobic septicemia indication 1976008
Bacterial septicemia indication 10001005 DOID:0040085
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Streptococcal septicemia indication 29577008
Pneumonia due to Streptococcus indication 34020007
Empyema of pleura indication 58554001 DOID:3798
Acne vulgaris indication 88616000
Infection of bone indication 111253001
Staphylococcal septicemia indication 111821004
Infectious disease of abdomen indication 128070006
Pneumococcal pneumonia indication 233607000
Gas gangrene caused by clostridium perfringens indication 266093005
Streptococcus pyogenes infection indication 302809008
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Aspiration pneumonia indication 422588002 DOID:3240
Infection due to anaerobic bacteria indication 423451008
Osteomyelitis due to Staphylococcus aureus indication 428783003
Skin and Skin Structure Anaerobic Infection indication
Anaerobic Tubo-Ovarian Abscess indication
Prevention of Bacterial Endocarditis indication
Anaerobic Lung Abscess indication
Anaerobic Endometritis indication
Clostridium Perfringens Empyema indication
Anaerobic Peritonitis indication
Anaerobic Joint Infection indication
Anaerobic Pelvic Cellulitis indication
Intra-Abdominal Anaerobic Abscess indication
Inflammatory Disease of Female Pelvic Organs indication
Pyrexia of unknown origin off-label use 7520000
Inhalational anthrax off-label use 11389007
Actinomycotic infection off-label use 11817007 DOID:8478
Babesiosis off-label use 21061004 DOID:9643
Sinusitis off-label use 36971009
Erysipelas off-label use 44653001 DOID:11330
Malaria off-label use 61462000 DOID:12365
Cutaneous anthrax off-label use 84980006 DOID:7426
Gastrointestinal anthrax off-label use 111798006 DOID:13386
Bacterial infection of skin off-label use 128936008
Toxoplasmosis off-label use 187192000 DOID:9965
Diverticulitis of gastrointestinal tract off-label use 271366000
Infective otitis media off-label use 312218008
Rosacea off-label use 398909004 DOID:8881
Pneumocystosis jiroveci pneumonia off-label use 415125002 DOID:11339
Toxoplasmosis associated with acquired immunodeficiency syndrome off-label use 421666009
Chloroquine Resistant Plasmodium Falciparum Malaria off-label use
Diabetic Foot Infection off-label use
Encephalitis due to Toxoplasmosis off-label use
Atopic dermatitis contraindication 24079001 DOID:3310
Crohn's disease contraindication 34000006
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Diarrhea contraindication 62315008
Ulcerative colitis contraindication 64766004 DOID:8577
Pseudomembranous enterocolitis contraindication 397683000
Bloody Stools contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 1.46 acidic
pKa2 6.51 acidic
pKa3 12.55 acidic
pKa4 13.71 acidic
pKa5 7.52 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 2% BASE CLINDESSE PADAGIS US N050793 Nov. 30, 2004 RX CREAM VAGINAL 6899890 April 27, 2023 METHOD OF TREATING BACTERIAL VAGINOSIS
1% EVOCLIN MYLAN N050801 Oct. 22, 2004 DISCN AEROSOL, FOAM TOPICAL 7374747 Jan. 23, 2024 TREATMENT OF ACNE VULGARIS
EQ 2% BASE CLINDESSE PADAGIS US N050793 Nov. 30, 2004 RX CREAM VAGINAL 9789057 Dec. 2, 2026 METHOD OF TREATING BACTERIAL VAGINOSIS
2.5%;EQ 1.2% BASE ACANYA BAUSCH N050819 Oct. 23, 2008 RX GEL TOPICAL 10220049 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
2.5%;EQ 1.2% BASE ACANYA BAUSCH N050819 Oct. 23, 2008 RX GEL TOPICAL 10624918 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
2.5%;EQ 1.2% BASE ACANYA BAUSCH N050819 Oct. 23, 2008 RX GEL TOPICAL 8663699 June 3, 2029 TREATMENT OF ACNE
2.5%;EQ 1.2% BASE ACANYA BAUSCH N050819 Oct. 23, 2008 RX GEL TOPICAL 8895070 June 3, 2029 TREATMENT OF ACNE
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 10137142 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 10220049 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 9504704 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 9504704 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 9504704 June 3, 2029 TREATMENT OF ACNE
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 9504704 June 3, 2029 TREATMENT OF ACNE VULGARIS
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 9561208 June 3, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
2.5%;EQ 1.2% BASE ACANYA BAUSCH N050819 Oct. 23, 2008 RX GEL TOPICAL 8288434 Aug. 5, 2029 TREATMENT OF ACNE
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 8288434 Aug. 5, 2029 TOPICAL TREATMENT OF ACNE VULGARIS
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 8288434 Aug. 5, 2029 TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 8288434 Aug. 5, 2029 TREATMENT OF ACNE
3.75%;EQ 1.2% BASE ONEXTON BAUSCH N050819 Nov. 24, 2014 RX GEL TOPICAL 8288434 Aug. 5, 2029 TREATMENT OF ACNE VULGARIS
EQ 2% BASE XACIATO DARE N215650 Dec. 7, 2021 RX GEL VAGINAL 11129896 Sept. 22, 2036 METHOD OF TREATING BACTERIAL VAGINOSIS BY SINGLE DOSE ADMINISTRATION OF A CLINDAMYCIN PHARMACEUTICAL GEL FORMULATION

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 1% BASE CLINDAMYCIN PHOSPHATE AMNEAL A214668 Aug. 5, 2022 RX GEL TOPICAL Feb. 1, 2023 COMPETITIVE GENERIC THERAPY
5%;1.2% CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE ENCUBE A212433 April 28, 2021 RX GEL TOPICAL March 13, 2023 COMPETITIVE GENERIC THERAPY
EQ 2% BASE XACIATO DARE N215650 Dec. 7, 2021 RX GEL VAGINAL Dec. 7, 2024 NEW PRODUCT
EQ 2% BASE XACIATO DARE N215650 Dec. 7, 2021 RX GEL VAGINAL Dec. 7, 2029 GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

None

External reference:

IDSource
4018084 VUID
N0000179085 NUI
D01073 KEGG_DRUG
4018084 VANDF
4019683 VANDF
C0055881 UMLSCUI
CHEBI:3746 CHEBI
CHEBI:3745 CHEBI
CLY PDB_CHEM_ID
CHEMBL3184512 ChEMBL_ID
C007084 MESH_SUPPLEMENTAL_RECORD_UI
EH6D7113I8 UNII
443385 PUBCHEM_CID
DB01190 DRUGBANK_ID
2582 RXNORM
29382 MMSL
367076 MMSL
3963 MMSL
41731 MMSL
4466 MMSL
4469 MMSL
4813 MMSL
d00043 MMSL
002794 NDDF
002796 NDDF
372786004 SNOMEDCT_US
37648000 SNOMEDCT_US
58883005 SNOMEDCT_US
C0008947 UMLSCUI
2550 INN_ID
446598 PUBCHEM_CID
D002981 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0302 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0302 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0302 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0602 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0602 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0602 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0728 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0728 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0775 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0775 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0870 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0870 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0901 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0901 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0901 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 26 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0902 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-0902 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 28 sections
Cleocin T HUMAN PRESCRIPTION DRUG LABEL 1 0009-1313 GEL 10 mg TOPICAL Export only 1 sections
Cleocin T HUMAN PRESCRIPTION DRUG LABEL 1 0009-1333 GEL 10 mg TOPICAL Export only 1 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3051 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 27 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3051 INJECTION, SOLUTION 150 mg INTRAMUSCULAR NDA 27 sections
Cleocin T HUMAN PRESCRIPTION DRUG LABEL 1 0009-3116 SOLUTION 10 mg TOPICAL NDA 23 sections
Cleocin T HUMAN PRESCRIPTION DRUG LABEL 1 0009-3116 SOLUTION 10 mg TOPICAL NDA 23 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3124 INJECTION, SOLUTION 150 mg INTRAVENOUS ANDA 28 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3124 INJECTION, SOLUTION 150 mg INTRAVENOUS ANDA 28 sections
Cleocin T HUMAN PRESCRIPTION DRUG LABEL 1 0009-3329 LOTION 10 mg TOPICAL NDA 23 sections
Cleocin T HUMAN PRESCRIPTION DRUG LABEL 1 0009-3329 LOTION 10 mg TOPICAL NDA 23 sections
Cleocin T HUMAN PRESCRIPTION DRUG LABEL 1 0009-3331 GEL 10 mg TOPICAL NDA 23 sections
Cleocin T HUMAN PRESCRIPTION DRUG LABEL 1 0009-3331 GEL 10 mg TOPICAL NDA 23 sections
Cleocin Phosphate HUMAN PRESCRIPTION DRUG LABEL 1 0009-3375 INJECTION, SOLUTION 12 mg INTRAVENOUS NDA 28 sections